Impact of Treatment Delay on the Prognosis of Patients with Ovarian Cancer: A Population-based Study Using the Surveillance, Epidemiology, and End Results Database
Affiliations
This study aimed to assess the impact of treatment delay on prognosis in patients with ovarian cancer. A retrospective analysis of patients with ovarian cancer in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015 was performed. Chi-square tests were used to assess baseline differences. The Kaplan-Meier method was used to evaluate the effect of different treatment intervals on survival outcomes in patients. Cox regression analyses were used to identify independent factors associated with ovarian cancer prognosis. Of the 21,590 patients included, 15,675 (72.6%), 5,582 (25.9%), and 333 (1.54%) were classified into the immediate-treatment (<1 month after diagnosis), intermediate-delay (1-2 month delayed), and long-delay groups (≥3 months delayed), respectively. The 5-year probability of overall survival (OS) was 61.4% in the immediate-treatment group, decreasing to 36.4% and 34.8% in the intermediate- and long-delay groups, respectively. Similar survival differences were also reflected in cancer-specific survival (CSS), with 5-year CSS probabilities of 66.7%, 42.6%, and 41.8% in the aforementioned groups, respectively. Patients in the intermediate-delay group showed poorer OS (adjusted hazard ratio [HR], 1.06; 95% confidence interval [CI], 1.02-1.11; p=0.006) and CSS (adjusted HR, 1.06; 95% CI, 1.01-1.11; p=0.012) than immediate-treatment group. Patients with delayed treatment had poorer OS and CSS. The patient's waiting time from diagnosis to initial treatment should be within 1 month.
FOXR2 in cancer development: emerging player and therapeutic opportunities.
Yang P, Sheykhhasan M, Heidari R, Chamanara M, Dama P, Ahmadieh-Yazdi A Oncol Res. 2025; 33(2):283-300.
PMID: 39866234 PMC: 11753994. DOI: 10.32604/or.2024.052939.
The Impact of Surgery Delay on Early-Stage Ovarian Cancer.
Zouzoulas D, Tsolakidis D, Sofianou I, Karalis T, Aristotelidis M, Tzitzis P Life (Basel). 2025; 15(1).
PMID: 39860062 PMC: 11766659. DOI: 10.3390/life15010122.
Chitti W, Insin P, Prueksaritanond N World J Oncol. 2025; 16(1):70-82.
PMID: 39850521 PMC: 11750756. DOI: 10.14740/wjon1990.
Habteyes A, Deressa J, Kassa R BMC Womens Health. 2025; 25(1):36.
PMID: 39849505 PMC: 11756220. DOI: 10.1186/s12905-025-03566-w.
Steventon L, Man K, Nicum S, Miller R, Peleg Hasson S, Shah S Oncologist. 2024; 29(11):e1532-e1539.
PMID: 39245440 PMC: 11546639. DOI: 10.1093/oncolo/oyae201.